Definitive Healthcare (NASDAQ:DH) Raised to “Strong-Buy” at Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

Several other analysts also recently weighed in on the company. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Barclays decreased their target price on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a report on Monday, December 8th. Morgan Stanley reiterated an “underperform” rating and issued a $3.50 price target on shares of Definitive Healthcare in a report on Thursday. Canaccord Genuity Group decreased their price objective on shares of Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Definitive Healthcare currently has an average rating of “Hold” and an average price target of $3.94.

Definitive Healthcare Stock Down 1.6%

NASDAQ:DH opened at $2.54 on Friday. The company has a market cap of $359.05 million, a PE ratio of -1.52 and a beta of 1.60. Definitive Healthcare has a twelve month low of $2.15 and a twelve month high of $5.68. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.41. The company’s 50 day moving average is $2.71 and its two-hundred day moving average is $3.47.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $60.05 million during the quarter, compared to analysts’ expectations of $59.51 million. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. Analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC increased its position in Definitive Healthcare by 2,456.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 144,284 shares of the company’s stock valued at $417,000 after acquiring an additional 138,640 shares during the period. Bank of Montreal Can acquired a new stake in Definitive Healthcare during the 2nd quarter worth approximately $71,000. Nuveen LLC purchased a new position in shares of Definitive Healthcare in the 1st quarter valued at approximately $300,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Definitive Healthcare by 44.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,046 shares of the company’s stock valued at $1,408,000 after purchasing an additional 110,894 shares during the period. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Definitive Healthcare during the second quarter worth approximately $77,000. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.